RTP Mobile Logo
Acute Leukemias Update, Issue 1, 2017
Released November 2017

Featuring interviews with Drs Daniel J DeAngelo and Amir T Fathi. (Audio Content)

CE Disclosures and Faculty Information

    The treatment of acute leukemias remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate requires careful consideration of patient-specific characteristics, physician expertise and available health-system resources. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Acute Leukemias Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies.


    • Appraise data on recent therapeutic advances and changing practice standards, including FDA approvals, in acute forms of leukemia, and integrate this information into current clinical care.
    • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information in treatment decision-making for patients with acute forms of leukemia.
    • Consider age, performance status and other disease-related factors in the identification of patients with acute lymphoblastic leukemia who are appropriate for targeted agents or chemotherapy.
    • Counsel patients regarding the incidence and manifestation of side effects and toxicities associated with newly approved and investigational agents and regimens in the treatment of acute forms of leukemia.
    • Identify the proposed mechanisms of action of and recall new data with investigational agents demonstrating promising activity in acute forms of leukemia, and refer appropriate patients for participation in ongoing trials evaluating these approaches.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity contains an audio component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYThe following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr DeAngeloConsulting Agreements: Amgen Inc, Daiichi Sankyo Inc, Incyte Corporation, Novartis, Pfizer Inc, Shire, Takeda Oncology. Dr FathiAdvisory Committee: Agios Pharmaceuticals Inc, Celgene Corporation, Pfizer Inc; Consulting Agreements: Amgen Inc, Celgene Corporation, MedImmune Inc, Seattle Genetics; Contracted Research: Celgene Corporation, Exelixis Inc, Seattle Genetics, Takeda Oncology.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation, Jazz Pharmaceuticals Inc, Novartis and Pfizer Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: November 2017
    Expiration date: November 2018

Acknowledge and close

Listen to audio:
Acute Leukemias Update, Issue 1, 2017
Released November 2017

Featuring interviews with Drs Daniel J DeAngelo and Amir T Fathi. (Audio Content)

Read print: